Acadia Pharmaceuticals
ACAD · Mid Cap · NYSE · Healthcare · Biotechnology
$19.71−$0.60 (-2.95%)
Market closed · opens in 1d 0hNext open: Monday, Oct 26, 9:30 AM ETFree AI brief
Get the full brief on ACAD
Free to track. No card required. Usually ready in 10-15 minutes.
Where ACAD sits today
Price, momentum, and the numbers behind the story.
52-week range
Low$19.69
High$28.35
Today $19.71
RSI (14)
46.5Neutral
03070100
Stocksbrew score
59/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
What Wall Street thinks
Where the analysts and the crowd stand, and what it's worth to know first.
Analyst price targets
Lowest
$16
Current price
$19.71
Median target
$33
Highest
$37
LowHigh
The business, by the numbers
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
RevenueTrend
✓ Good things about the company
Price / sales
Strong · Low price-to-sales
2.89x
ROIC
Strong · Excellent capital returns
19.8%
ROE
Favorable · 37.3% - strong capital efficiency
35.7%
Debt / equity
Favorable · 0.04 - strong leverage
0.06x
Current ratio
Strong · Good liquidity position
3.39x
⚠ Things to watch
Forward P/E
Needs attention · 76% above avg
24.31x
EV / EBITDA
Rich · Earnings can't support price
24.51x
How it stacks up against its peers
ACAD against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $3.29B | 8.6 | +11.8% | 59 |
 | $10.93B | 20.8 | +19.7% | 78 |
 | $29.41B | 30.8 | +15.5% | 78 |
 | $4.30B | 12.2 | +13.5% | 78 |
 | $1.20T | 43.3 | +49.6% | 77 |